We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) to Report Q3 Earnings: What's in the Offing?
Read MoreHide Full Article
McKesson Corporation’s (MCK - Free Report) third-quarter fiscal 2020 results are scheduled to release on Feb 4, before market open.
For the last reported quarter, the company has an earnings surprise of 0.00%. Further, it has an average positive surprise of 4.2% for the trailing four quarters.
Let’s take a look at how things are shaping up prior to this announcement.
How Are Q3 Estimates Placed?
The Zacks Consensus Estimate for McKesson’s fiscal third-quarter earnings per share is pegged at $3.52, suggesting year-over-year growth of 3.5%. The same for revenues stands at $59.42 billion, indicating growth of 5.7% from the year-ago reported figure.
Factors to Consider
McKesson expects fiscal third-quarter results to reflect segmental strength.
The U.S. Pharmaceutical and Specialty Solutions segment is likely to have acted as a key catalyst.
Notably, the segment is likely to have benefited from branded, generic and over-the-counter pharmaceuticals. Also, the company’s broad spectrum of specialty biopharmaceutical providers and manufacturers are expected to have contributed majorly in the third quarter. Per management, the company’s ClarusONE Sourcing venture is also expected to have driven the segment substantially. Independent pharmacies, who are important customers for McKesson, are also believed to have aided U.S. Pharmaceutical and Specialty Solutions.
Reflective of these, the Zacks Consensus Estimate for the segment’s third-quarter revenues is pegged at $45.39 billion, calling for a rise of 2.5% year over year.
Apart from this, management is optimistic about contributions from the Medical-Surgical Solutions segment, driven by acquisitions and growth in the Primary Care and Extended Care businesses. Notably, the takeover of Medical Specialties Distributor is expected to have proven accretive in the quarter to be reported.
The Zacks Consensus Estimate for the segment’s third-quarter revenues is pinned at $2.13 billion, suggesting 6% growth year over year.
Meanwhile, revenues at the European Pharmaceutical Solutions unit are expected to remain flat year over year, after a disappointing show in the last reported quarter. Notably, the Zacks Consensus Estimate for the segment’s third-quarter revenues stands at $6.91 billion. The company’s recent joint venture with MedTech giant Walgreens (WBA - Free Report) is expected to have boosted McKesson’s European Pharmaceutical Solutions segment. In fact, management at McKesson expects revenues to improve in Europe in the second half of fiscal 2020 compared to the first half.
Earnings Whispers
Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise. That is precisely the case here as you will see below.
Earnings ESP: McKesson has an Earnings ESP of +0.63%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are a few other medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
DexCom (DXCM - Free Report) has an Earnings ESP of +17.07% and a Zacks Rank #2.
AmerisourceBergen has an Earnings ESP of +0.82% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
McKesson (MCK) to Report Q3 Earnings: What's in the Offing?
McKesson Corporation’s (MCK - Free Report) third-quarter fiscal 2020 results are scheduled to release on Feb 4, before market open.
For the last reported quarter, the company has an earnings surprise of 0.00%. Further, it has an average positive surprise of 4.2% for the trailing four quarters.
Let’s take a look at how things are shaping up prior to this announcement.
How Are Q3 Estimates Placed?
The Zacks Consensus Estimate for McKesson’s fiscal third-quarter earnings per share is pegged at $3.52, suggesting year-over-year growth of 3.5%. The same for revenues stands at $59.42 billion, indicating growth of 5.7% from the year-ago reported figure.
Factors to Consider
McKesson expects fiscal third-quarter results to reflect segmental strength.
The U.S. Pharmaceutical and Specialty Solutions segment is likely to have acted as a key catalyst.
Notably, the segment is likely to have benefited from branded, generic and over-the-counter pharmaceuticals. Also, the company’s broad spectrum of specialty biopharmaceutical providers and manufacturers are expected to have contributed majorly in the third quarter. Per management, the company’s ClarusONE Sourcing venture is also expected to have driven the segment substantially. Independent pharmacies, who are important customers for McKesson, are also believed to have aided U.S. Pharmaceutical and Specialty Solutions.
Reflective of these, the Zacks Consensus Estimate for the segment’s third-quarter revenues is pegged at $45.39 billion, calling for a rise of 2.5% year over year.
McKesson Corporation Price and EPS Surprise
McKesson Corporation price-eps-surprise | McKesson Corporation Quote
Apart from this, management is optimistic about contributions from the Medical-Surgical Solutions segment, driven by acquisitions and growth in the Primary Care and Extended Care businesses. Notably, the takeover of Medical Specialties Distributor is expected to have proven accretive in the quarter to be reported.
The Zacks Consensus Estimate for the segment’s third-quarter revenues is pinned at $2.13 billion, suggesting 6% growth year over year.
Meanwhile, revenues at the European Pharmaceutical Solutions unit are expected to remain flat year over year, after a disappointing show in the last reported quarter. Notably, the Zacks Consensus Estimate for the segment’s third-quarter revenues stands at $6.91 billion. The company’s recent joint venture with MedTech giant Walgreens (WBA - Free Report) is expected to have boosted McKesson’s European Pharmaceutical Solutions segment. In fact, management at McKesson expects revenues to improve in Europe in the second half of fiscal 2020 compared to the first half.
Earnings Whispers
Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise. That is precisely the case here as you will see below.
Earnings ESP: McKesson has an Earnings ESP of +0.63%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: McKesson carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks Worth a Look
Here are a few other medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
DexCom (DXCM - Free Report) has an Earnings ESP of +17.07% and a Zacks Rank #2.
AmerisourceBergen has an Earnings ESP of +0.82% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>